- Home
- LGCB vs CANF Comparison
LGCB vs CANF Comparison
Compare LGCB & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCB
- CANF
- Stock Information
- Founded
- LGCB 2011
- CANF 1994
- Country
- LGCB Japan
- CANF Israel
- Employees
- LGCB N/A
- CANF N/A
- Industry
- LGCB
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- LGCB
- CANF Health Care
- Exchange
- LGCB Nasdaq
- CANF Nasdaq
- Market Cap
- LGCB 8.4M
- CANF 7.9M
- IPO Year
- LGCB 2023
- CANF N/A
- Fundamental
- Price
- LGCB $1.97
- CANF $1.17
- Analyst Decision
- LGCB
- CANF Strong Buy
- Analyst Count
- LGCB 0
- CANF 2
- Target Price
- LGCB N/A
- CANF $14.00
- AVG Volume (30 Days)
- LGCB 1.1M
- CANF 412.3K
- Earning Date
- LGCB 05-06-2025
- CANF 05-06-2025
- Dividend Yield
- LGCB N/A
- CANF N/A
- EPS Growth
- LGCB N/A
- CANF N/A
- EPS
- LGCB N/A
- CANF N/A
- Revenue
- LGCB $10,289,681.00
- CANF $674,000.00
- Revenue This Year
- LGCB N/A
- CANF $461.72
- Revenue Next Year
- LGCB N/A
- CANF N/A
- P/E Ratio
- LGCB N/A
- CANF N/A
- Revenue Growth
- LGCB N/A
- CANF N/A
- 52 Week Low
- LGCB $1.22
- CANF $1.22
- 52 Week High
- LGCB $57.05
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- LGCB 53.20
- CANF 37.12
- Support Level
- LGCB $1.68
- CANF $1.14
- Resistance Level
- LGCB $2.07
- CANF $1.27
- Average True Range (ATR)
- LGCB 0.36
- CANF 0.12
- MACD
- LGCB 0.04
- CANF -0.02
- Stochastic Oscillator
- LGCB 63.56
- CANF 4.46
About LGCB Linkage Global Inc
Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The Company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).